ClinicalTrials.gg
CompletedNCT00875277Updated Mar 12, 2025Results posted

A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products

A Phase 2 interventional study of LEO 29102 cream and LEO 29102 Cream Vehicle in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by LEO Pharma · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing betamethasone dipropionate in Psoriasis — 1 open to participants now, 1 under way, 1 of them phase 3. betamethasone dipropionate · Psoriasis.

Enrollment
27th of 29
24 · median 224
Started
2009
with 1 other
Phase 2
9 of 29
none open now
Registered
9th of 29
by date
Lead sponsor
16 of 29
LEO Pharma

Among the 29 studies testing betamethasone dipropionate in Psoriasis, this one is the 27th largest by enrollment, is one of 2 that started in 2009, is one of 9 in phase 2, and was the 9th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 29 studies testing betamethasone dipropionate in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About betamethasone dipropionate

betamethasone dipropionate: first FDA approval 1975 (DIPROSONE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing betamethasone dipropionate in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this trial is to evaluate the anti-psoriatic effect of LEO 29102 cream and its combination with calcipotriol and betamethasone using a psoriasis plaque test method.

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: (in summary)

  • Subjects having understood and signed an form
  • All skin types
  • Subjects with a diagnosis of psoriasis vulgaris with lesions located on arms, legs or trunk. The lesions must have a total size suitable for application. The subjects should be asked if their lesions have been stable
  • Subjects willing and able to follow all the study procedures and complete the whole study
  • Subjects affiliated to social security system

Exclusion Criteria: (in summary)

  • Females who are pregnant, of and who wish to become pregnant during the study, or who are breast feeding
  • Subjects using biological therapies (marketed or not marketed) with a possible effect on psoriasis (e.g. alefacept, efalizumab, etanercept, infliximab, adalimumab) within 12 weeks prior to study drug administration
  • Systemic treatments with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., , vitamin D-analogues, retinoids, ) within the 4-week period prior to randomisation
  • Subjects using one of the following topical drugs for the treatment of psoriasis within four (4) weeks prior to study drug administration: - Potent or very potent (WHO group III-IV) corticosteroids - PUVA or Grenz ray therapy
  • Subjects using one of the following topical drugs for the treatment of psoriasis within two (2) weeks prior to study drug administration: - WHO group I-II corticosteroids - Topical retinoids - Vitamin D-analogues - Topical immunomodulators (e.g. macrolides) - Anthracen derivatives - Tar - Salicylic acid - UVB therapy
  • Subjects with skin manifestations in relation to syphilis or tuberculosis, rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers and wounds within the plaque test areas
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    LEO 29102 cream

    LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks

    Drug: LEO 29102 cream

  • Placebo comparator
    LEO 29102 Cream Vehicle

    LEO 29102 cream vehicle applied topically twice daily for 4 weeks.

    Drug: LEO 29102 Cream Vehicle

  • Experimental
    Betamethasone Dipropionate Cream

    Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.

    Drug: Betamethasone Dipropionate Cream

  • Experimental
    LEO 29102 Plus Calcipotriol Cream

    LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.

    Drug: LEO 29102 Plus Calcipotriol Cream

  • Experimental
    LEO 29102 Plus Betamethasone Dipropionate

    LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.

    Drug: LEO 29102 Plus Betamethasone Dipropionate

  • Active comparator
    Daivobet® Ointment

    Daivobet® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.

    Drug: Daivobet® Ointment

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1)

    The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Erythema: 0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red Scaling: 0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales Infiltration: 0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).

    Time frame: From baseline (Day 1) to end of treatment (Day 29)

Secondary outcomes

  1. Change in Single Clinical Symptom Score: Erythema, Scaling, Infiltration Compared to Baseline

    The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Erythema: 0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red Scaling: 0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales Infiltration: 0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).

    Time frame: From baseline (Day 1) to end of treatment (Day 29)

  2. Change in Erythema Compared to Baseline

    The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale. The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Erythema: 0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red

    Time frame: At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22 and Day 25

  3. Change in Scaling Compared to Baseline

    The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale. The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Scaling: 0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales

    Time frame: At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25

  4. Change in Infiltration Compared to Baseline

    The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale. The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Infiltration: 0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration

    Time frame: At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25

  5. Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline

    The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Erythema: 0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red Scaling: 0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales Infiltration: 0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).

    Time frame: At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25

  6. Ultrasonography: Change in Lesions Thickness From Baseline Measured by Ultrasound

    The lesion thickness was measured by ultrasound at baseline, Day 8, Day 15, Day 22 and end of treatment.

    Time frame: At Day 8, Day 15, Day 22 and end of treatment

  7. Biomarkers by Immunochemistry

    3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement. Cells counted per mm\^2 were cells that were positive for the indicated biomarker.

    Time frame: At end of treatment

  8. Biomarkers by Immunochemistry: Epidermal Differentiation

    3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement.

    Time frame: At end of treatment

  9. Biomarkers by Immunochemistry: Epidermal Proliferation

    3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement. By measurement of the cell-cycle marker, Ki-67 protein, an evaluation of the degree of skin cell proliferation and thereby epidermal proliferation could be obtained. Cells counted per mm\^2 were cells that were positive for the indicated biomarker.

    Time frame: At end of treatment

  10. Pathology and Histology by Treatment

    Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. The extent of the following parameters were measured in scored semi-quantitatively (semi) on blinded haematoxylin and eosin (HE) sections. Semi-quantitative scoring was categorized as No (0), mild (1), moderate (2), marked (3) or severe (4). In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum) the tissue was classified by the characteristics seen below: * Morphology of epidermis * Stratum corneum (semi (extent of)) * Stratum granulosum (semi (extent of)) * Parakeratosis (semi (extent of)) * Infiltration of inflammatory cells (semi (extent of))

    Time frame: At end of treatment

  11. Pathology and Histology by Treatment: Epidermal Thickness

    Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum), the tissue was classified by the characteristic epidermal thickness. This was measured in the absolute number of µm measured on blinded haematoxylin and eosin (HE) sections..

    Time frame: At end of treatment

  12. Pathology and Histology by Treatment: Frequency of Neutrophil Abscesses

    Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum), the tissue was classified by the characteristic of frequency of neutrophil microabscesses (Monroe´s abscess). This was measured in absolute number of cells that were positive for the marker on blinded haematoxylin and eosin (HE) sections.

    Time frame: At end of treatment

07

Results

Posted Dec 11, 2019

Participant flow

Participants were treated with the investigational medicinal products for 4 weeks followed by a 10-day follow-up period.

Participant flow — Overall Study
MilestoneAll Randomized Participants
Started24
Completed24
Not completed0

Outcome measures

PrimaryChange in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1)

The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Erythema: 0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red Scaling: 0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales Infiltration: 0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).

Time frame:
From baseline (Day 1) to end of treatment (Day 29)
Reported as:
Mean · score on a scale
Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1)
score on a scaleLEO 29102 Cream VehicleBetamethasone Dipropionate CreamLEO 29102 CreamLEO 29102 Plus Calcipotriol CreamLEO 29102 Plus Betamethasone DipropionateDaivobet® Ointment
Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1)-1.60 ± 1.18-4.96 ± 1.99-3.04 ± 1.34-3.96 ± 1.49-5.56 ± 1.28-6.10 ± 1.06
Statistical analysis
  • LEO 29102 Cream Vehicle vs Betamethasone Dipropionate Cream · t-test, 2 sided · p = <0.001
  • LEO 29102 Cream Vehicle vs LEO 29102 Cream · t-test, 2 sided · p = <0.001
  • LEO 29102 Cream Vehicle vs LEO 29102 Plus Calcipotriol Cream · t-test, 2 sided · p = <0.001
  • LEO 29102 Cream Vehicle vs LEO 29102 Plus Betamethasone Dipropionate · t-test, 2 sided · p = <0.001
  • LEO 29102 Cream Vehicle vs Daivobet® Ointment · t-test, 2 sided · p = <0.001
  • Betamethasone Dipropionate Cream vs LEO 29102 Cream · t-test, 2 sided · p = <0.001
  • Betamethasone Dipropionate Cream vs LEO 29102 Plus Calcipotriol Cream · t-test, 2 sided · p = 0.035
  • Betamethasone Dipropionate Cream vs LEO 29102 Plus Betamethasone Dipropionate · t-test, 2 sided · p = 0.082
  • Betamethasone Dipropionate Cream vs Daivobet® Ointment · t-test, 2 sided · p = 0.009
  • LEO 29102 Cream vs LEO 29102 Plus Calcipotriol Cream · t-test, 2 sided · p = 0.012
  • LEO 29102 Cream vs LEO 29102 Plus Betamethasone Dipropionate · t-test, 2 sided · p = <0.001
  • LEO 29102 Cream vs Daivobet® Ointment · t-test, 2 sided · p = <0.001
  • LEO 29102 Plus Calcipotriol Cream vs LEO 29102 Plus Betamethasone Dipropionate · t-test, 2 sided · p = <0.001
  • LEO 29102 Plus Calcipotriol Cream vs Daivobet® Ointment · t-test, 2 sided · p = <0.001
  • LEO 29102 Plus Betamethasone Dipropionate vs Daivobet® Ointment · t-test, 2 sided · p = 0.089
SecondaryChange in Single Clinical Symptom Score: Erythema, Scaling, Infiltration Compared to Baseline

The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Erythema: 0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red Scaling: 0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales Infiltration: 0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).

Time frame:
From baseline (Day 1) to end of treatment (Day 29)
Reported as:
Mean · score on a scale
Change in Single Clinical Symptom Score: Erythema, Scaling, Infiltration Compared to Baseline
score on a scaleLEO 29102 Cream VehicleBetamethasone Dipropionate CreamLEO 29102 CreamLEO 29102 Plus Calcipotriol CreamLEO 29102 Plus Betamethasone DipropionateDaivobet® Ointment
Erythema-0.42 ± 0.48-1.71 ± 0.81-0.90 ± 0.55-1.19 ± 0.70-1.85 ± 0.63-1.88 ± 0.45
Infiltration-0.46 ± 0.33-1.46 ± 0.75-0.85 ± 0.52-1.17 ± 0.50-1.75 ± 0.53-2.04 ± 0.55
Scaliness-0.73 ± 0.57-1.79 ± 0.62-1.29 ± 0.51-1.60 ± 0.55-1.96 ± 0.41-2.19 ± 0.41
SecondaryChange in Erythema Compared to Baseline

The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale. The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Erythema: 0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red

Time frame:
At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22 and Day 25
Reported as:
Mean · units on a scale
Change in Erythema Compared to Baseline
units on a scaleLEO 29102 Cream VehicleBetamethasone Dipropionate CreamLEO 29102 CreamLEO 29102 Plus Calcipotriol CreamLEO 29102 Plus Betamethasone DipropionateDaivobet® Ointment
Visit 5 (Day 4)-0.04 ± 0.25-0.21 ± 0.29-0.02 ± 0.18-0.08 ± 0.24-0.40 ± 0.42-0.38 ± 0.42
Visit 8 (Day 8)-0.08 ± 0.38-0.67 ± 0.46-0.31 ± 0.32-0.29 ± 0.29-0.92 ± 0.43-0.88 ± 0.56
Visit 11 (Day 11)-0.23 ± 0.33-0.94 ± 0.47-0.46 ± 0.33-0.44 ± 0.37-1.17 ± 0.43-1.19 ± 0.66
Visit 14 (Day 15)-0.40 ± 0.36-1.23 ± 0.69-0.60 ± 0.36-0.77 ± 0.42-1.46 ± 0.59-1.40 ± 0.66
Visit 17 (Day 18)-0.44 ± 0.40-1.33 ± 0.76-0.75 ± 0.42-0.98 ± 0.40-1.71 ± 0.61-1.63 ± 0.56
Visit 20 (Day 22)-0.46 ± 0.49-1.48 ± 0.80-0.83 ± 0.55-1.04 ± 0.51-1.75 ± 0.66-1.85 ± 0.60
Visit 23 (Day 25)-0.42 ± 0.43-1.54 ± 0.81-0.85 ± 0.54-1.08 ± 0.50-1.83 ± 0.72-1.94 ± 0.54
SecondaryChange in Scaling Compared to Baseline

The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale. The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Scaling: 0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales

Time frame:
At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25
Reported as:
Mean · units on a scale
Change in Scaling Compared to Baseline
units on a scaleLEO 29102 Cream VehicleBetamethasone Dipropionate CreamLEO 29102 CreamLEO 29102 Plus Calcipotriol CreamLEO 29102 Plus Betamethasone DipropionateDaivobet® Ointment
Visit 5 (Day 4)-0.17 ± 0.35-0.31 ± 0.41-0.13 ± 0.30-0.21 ± 0.41-0.33 ± 0.43-0.52 ± 0.38
Visit 8 (Day 8)-0.27 ± 0.42-0.88 ± 0.61-0.44 ± 0.58-0.63 ± 0.58-1.17 ± 0.67-1.19 ± 0.48
Visit 11 (Day 11)-0.40 ± 0.33-1.15 ± 0.54-0.63 ± 0.42-0.71 ± 0.61-1.48 ± 0.58-1.92 ± 0.55
Visit 14 (Day 15)-0.52 ± 0.52-1.33 ± 0.64-0.73 ± 0.47-1.00 ± 0.55-1.67 ± 0.58-2.04 ± 0.49
Visit 17 (Day 18)-0.65 ± 0.45-1.56 ± 0.60-0.90 ± 0.47-1.15 ± 0.54-1.83 ± 0.58-2.13 ± 0.49
Visit 20 (Day 22)-0.54 ± 0.29-1.54 ± 0.62-0.81 ± 0.44-1.27 ± 0.42-1.75 ± 0.53-2.19 ± 0.38
Visit 23 (Day 25)-0.75 ± 0.42-1.81 ± 0.60-1.17 ± 0.55-1.46 ± 0.57-2.00 ± 0.42-2.21 ± 0.36
SecondaryChange in Infiltration Compared to Baseline

The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale. The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Infiltration: 0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration

Time frame:
At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25
Reported as:
Mean · units on a scale
Change in Infiltration Compared to Baseline
units on a scaleLEO 29102 Cream VehicleBetamethasone Dipropionate CreamLEO 29102 CreamLEO 29102 Plus Calcipotriol CreamLEO 29102 Plus Betamethasone DipropionateDaivobet® Ointment
Visit 5 (Day 4)-0.06 ± 0.27-0.10 ± 0.29-0.04 ± 0.200.00 ± 0.21-0.27 ± 0.25-0.29 ± 0.33
Visit 8 (Day 8)-0.06 ± 0.31-0.38 ± 0.34-0.13 ± 0.34-0.29 ± 0.51-0.73 ± 0.47-0.79 ± 0.44
Visit 11 (Day 11)-0.13 ± 0.37-0.77 ± 0.51-0.31 ± 0.38-0.46 ± 0.39-1.06 ± 0.50-1.29 ± 0.62
Visit 14 (Day 15)-0.25 ± 0.33-0.98 ± 0.60-0.42 ± 0.43-0.69 ± 0.38-1.35 ± 0.65-1.79 ± 0.59
Visit 17 (Day 18)-0.33 ± 0.35-1.10 ± 0.61-0.58 ± 0.46-0.75 ± 0.39-1.50 ± 0.63-1.94 ± 0.61
Visit 20 (Day 22)-0.31 ± 0.29-1.25 ± 0.66-0.56 ± 0.47-0.90 ± 0.33-1.67 ± 0.62-1.98 ± 0.52
Visit 23 (Day 25)-0.38 ± 0.34-1.35 ± 0.73-0.73 ± 0.47-1.06 ± 0.40-1.67 ± 0.60-2.02 ± 0.54
SecondaryChange in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline

The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Erythema: 0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red Scaling: 0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales Infiltration: 0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).

Time frame:
At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25
Reported as:
Mean · score on a scale
Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline
score on a scaleLEO 29102 Cream VehicleBetamethasone Dipropionate CreamLEO 29102 CreamLEO 29102 Plus Calcipotriol CreamLEO 29102 Plus Betamethasone DipropionateDaivobet® Ointment
Visit 5 (Day 4)-0.27 ± 0.66-0.63 ± 0.80-0.19 ± 0.53-0.29 ± 0.66-1.00 ± 0.88-1.19 ± 0.86
Visit 8 (Day 8)-0.42 ± 0.78-1.92 ± 1.18-0.88 ± 0.97-1.21 ± 1.07-2.81 ± 1.26-2.85 ± 1.17
Visit 11 (Day 11)-0.75 ± 0.75-2.85 ± 1.26-1.40 ± 0.90-1.60 ± 1.11-3.71 ± 1.28-4.40 ± 1.42
Visit 14 (Day 15)-1.17 ± 0.89-3.54 ± 1.66-1.75 ± 1.12-2.46 ± 1.00-4.48 ± 1.56-5.23 ± 1.41
Visit 17 (Day 18)-1.42 ± 0.95-4.00 ± 1.72-2.23 ± 1.11-2.88 ± 0.99-5.04 ± 1.46-5.69 ± 1.30
Visit 20 (Day 22)-1.31 ± 0.83-4.27 ± 1.92-2.21 ± 1.20-3.21 ± 0.98-5.17 ± 1.64-6.02 ± 1.08
Visit 23 (Day 25)-1.54 ± 0.97-4.71 ± 1.99-2.75 ± 1.32-3.60 ± 1.25-5.50 ± 1.47-6.17 ± 0.87
SecondaryUltrasonography: Change in Lesions Thickness From Baseline Measured by Ultrasound

The lesion thickness was measured by ultrasound at baseline, Day 8, Day 15, Day 22 and end of treatment.

Time frame:
At Day 8, Day 15, Day 22 and end of treatment
Reported as:
Mean · mm
Ultrasonography: Change in Lesions Thickness From Baseline Measured by Ultrasound
mmLEO 29102 Cream VehicleBetamethasone Dipropionate CreamLEO 29102 CreamLEO 29102 Plus Calcipotriol CreamLEO 29102 Plus Betamethasone DipropionateDaivobet® Ointment
Visit 8 (Day 8)0.05 ± 0.22-0.14 ± 0.320.03 ± 0.240.00 ± 0.24-0.30 ± 0.27-0.39 ± 0.30
Visit 14 (Day 15)-0.05 ± 0.23-0.45 ± 0.39-0.16 ± 0.31-0.25 ± 0.36-0.51 ± 0.32-0.68 ± 0.46
Visit 20 (Day 22)-0.07 ± 0.27-0.54 ± 0.37-0.15 ± 0.19-0.24 ± 0.32-0.57 ± 0.34-0.68 ± 0.39
Visit 26 (Day 29)-0.13 ± 0.30-0.63 ± 0.39-0.30 ± 0.31-0.38 ± 0.30-0.68 ± 0.34-0.78 ± 0.43
SecondaryBiomarkers by Immunochemistry

3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement. Cells counted per mm\^2 were cells that were positive for the indicated biomarker.

Time frame:
At end of treatment
Reported as:
Mean · cells/mm^2
Biomarkers by Immunochemistry
cells/mm^2LEO 29102 Cream VehicleBetamethasone Dipropionate CreamLEO 29102 CreamLEO 29102 Plus Calcipotriol CreamLEO 29102 Plus Betamethasone DipropionateDaivobet® Ointment
Macrophages: CD163313.9 ± 97.28197.4 ± 69.51291.2 ± 100.8383.5 ± 488.6178.2 ± 27.96172.9 ± 40.61
Dendritic cells CD1a233.8 ± 113.942.14 ± 27.81229.3 ± 134.2244.0 ± 118.934.31 ± 20.0056.34 ± 33.81
T-cell biomarker CD3593.8 ± 243.9124.5 ± 105.9464.2 ± 275.9492.7 ± 280.4126.1 ± 95.57143.9 ± 161.5
Angiogenesis: CD31430.7 ± 165.7216.3 ± 100.1331.1 ± 120.9348.8 ± 158.1184.2 ± 38.84186.6 ± 51.62
T-cell biomarker: CD4284.3 ± 123.959.17 ± 41.78246.4 ± 148.0239.0 ± 147.355.56 ± 44.0366.95 ± 55.07
T-cell biomarker: CD45RO752.0 ± 183.1101.6 ± 78.14630.1 ± 318.8643.6 ± 370.4121.6 ± 50.39218.2 ± 258.7
Macrophages: CD68370.8 ± 58.56120.3 ± 61.57323.1 ± 114.2303.8 ± 117.8142.1 ± 58.47156.8 ± 44.82
T-cell biomarker: CD8280.5 ± 156.060.05 ± 61.95220.7 ± 123.9253.2 ± 171.966.35 ± 53.3065.05 ± 72.00
SecondaryBiomarkers by Immunochemistry: Epidermal Differentiation

3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement.

Time frame:
At end of treatment
Reported as:
Mean · %, positive area/total area
Biomarkers by Immunochemistry: Epidermal Differentiation
%, positive area/total areaLEO 29102 Cream VehicleBetamethasone Dipropionate CreamLEO 29102 CreamLEO 29102 Plus Calcipotriol CreamLEO 29102 Plus Betamethasone DipropionateDaivobet® Ointment
Epidermal differentiation: CK100.76 ± 0.140.89 ± 0.150.77 ± 0.140.75 ± 0.110.93 ± 0.080.89 ± 0.25
Epidermal differentiation: CK160.11 ± 0.140.00 ± 0.000.08 ± 0.110.02 ± 0.040.01 ± 0.010.00 ± 0.01
SecondaryBiomarkers by Immunochemistry: Epidermal Proliferation

3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement. By measurement of the cell-cycle marker, Ki-67 protein, an evaluation of the degree of skin cell proliferation and thereby epidermal proliferation could be obtained. Cells counted per mm\^2 were cells that were positive for the indicated biomarker.

Time frame:
At end of treatment
Reported as:
Mean · cells/mm^2
Biomarkers by Immunochemistry: Epidermal Proliferation
cells/mm^2LEO 29102 Cream VehicleBetamethasone Dipropionate CreamLEO 29102 CreamLEO 29102 Plus Calcipotriol CreamLEO 29102 Plus Betamethasone DipropionateDaivobet® Ointment
Biomarkers by Immunochemistry: Epidermal Proliferation554.1 ± 391.919.45 ± 28.69443.3 ± 298.6354.3 ± 198.220.50 ± 29.1193.49 ± 134.9
SecondaryPathology and Histology by Treatment

Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. The extent of the following parameters were measured in scored semi-quantitatively (semi) on blinded haematoxylin and eosin (HE) sections. Semi-quantitative scoring was categorized as No (0), mild (1), moderate (2), marked (3) or severe (4). In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum) the tissue was classified by the characteristics seen below: * Morphology of epidermis * Stratum corneum (semi (extent of)) * Stratum granulosum (semi (extent of)) * Parakeratosis (semi (extent of)) * Infiltration of inflammatory cells (semi (extent of))

Time frame:
At end of treatment
Reported as:
Mean · score on a scale
Pathology and Histology by Treatment
score on a scaleLEO 29102 Cream VehicleBetamethasone Dipropionate CreamLEO 29102 CreamLEO 29102 Plus Calcipotriol CreamLEO 29102 Plus Betamethasone DipropionateDaivobet® Ointment
Infiltration of inflammatory cells1.50 ± 0.800.17 ± 0.411.52 ± 0.791.53 ± 0.940.50 ± 0.550.67 ± 1.03
Parakeratosis1.67 ± 1.150.00 ± 0.001.39 ± 1.341.35 ± 1.110.00 ± 0.000.17 ± 0.41
Stratum Corneum1.83 ± 0.830.33 ± 0.521.52 ± 0.901.41 ± 0.940.50 ± 0.550.33 ± 0.82
Stratum Granulosum1.42 ± 1.240.17 ± 0.411.04 ± 1.261.00 ± 1.170.00 ± 0.000.17 ± 0.41
SecondaryPathology and Histology by Treatment: Epidermal Thickness

Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum), the tissue was classified by the characteristic epidermal thickness. This was measured in the absolute number of µm measured on blinded haematoxylin and eosin (HE) sections..

Time frame:
At end of treatment
Reported as:
Mean · µm
Pathology and Histology by Treatment: Epidermal Thickness
µmLEO 29102 Cream VehicleBetamethasone Dipropionate CreamLEO 29102 CreamLEO 29102 Plus Calcipotriol CreamLEO 29102 Plus Betamethasone DipropionateDaivobet® Ointment
Pathology and Histology by Treatment: Epidermal Thickness254.6 ± 58.6873.81 ± 20.61187.5 ± 79.65176.4 ± 49.0568.48 ± 18.1666.90 ± 44.53
SecondaryPathology and Histology by Treatment: Frequency of Neutrophil Abscesses

Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum), the tissue was classified by the characteristic of frequency of neutrophil microabscesses (Monroe´s abscess). This was measured in absolute number of cells that were positive for the marker on blinded haematoxylin and eosin (HE) sections.

Time frame:
At end of treatment
Reported as:
Mean · cells/mm^2
Pathology and Histology by Treatment: Frequency of Neutrophil Abscesses
cells/mm^2LEO 29102 Cream VehicleBetamethasone Dipropionate CreamLEO 29102 CreamLEO 29102 Plus Calcipotriol CreamLEO 29102 Plus Betamethasone DipropionateDaivobet® Ointment
Pathology and Histology by Treatment: Frequency of Neutrophil Abscesses0.14 ± 0.260.00 ± 0.000.15 ± 0.350.17 ± 0.300.00 ± 0.000.05 ± 0.13

Adverse events

Collected over From baseline to end of Follow-up (Day 43±2). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Randomized Participants—0/24 (0%)8/24 (33.3%)
Most frequent other events
Most frequent other events
EventAll Randomized Participants
HeadacheNervous system disorders4/24
DiarrhoeaGastrointestinal disorders3/24
DiverticulitisGastrointestinal disorders1/24
ToothacheGastrointestinal disorders1/24
HordeolumInfections and infestations1/24
NasopharyngitisInfections and infestations1/24
Postoperative infectionInfections and infestations1/24
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/24
CoughRespiratory, thoracic and mediastinal disorders1/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Randomized Participants
Mean50.7 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)All Randomized Participants
Female6
Male18
Region of Enrollment
Region of Enrollment(participants)All Randomized Participants
France24
08

Study locations

1 site
  • LEO Pharma site
    Saint-Quentin-en-Yvelines, France
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of May 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2019, 10 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2009
First posted
Apr 3, 2009
Start
Apr 2009
Primary completionActual
May 2009
CompletionActual
Jul 2009
Results first posted
Dec 11, 2019
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00875277
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Apr 3, 2009
Start date
Apr 2009
Primary completion
May 2009
Completion
Jul 2009
Results posted
Dec 11, 2019
Last update
Mar 12, 2025

Study contacts

Director, International Clinical Development, MD
study director · LEO Pharma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: 2-(6-(2-(3,5-dichloro-4-pyridyl)acetyl)-2,3-dimethoxyphenoxy)-N-propylacetamide · Betamethasone dipropionate · Calcipotriene

Start the discussion